Article citationsMore>>

Sangro, B., Kudo, M., Erinjeri, J.P., Qin, S., Ren, Z., Chan, S.L., et al. (2025) Durvalumab with or without Bevacizumab with Transarterial Chemoembolisation in Hepatocellular Carcinoma (EMERALD-1): A Multiregional, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. The Lancet, 405, 216-232.
https://doi.org/10.1016/s0140-6736(24)02551-0

has been cited by the following article:

• TITLE: Research Progress of TACE Combined with Immunotherapy and Anti-Vascular Triple Therapy in Unresectable Hepatocellular Carcinoma

  AUTHORS: Yanxiong Guo, Weiguo Xu

  KEYWORDS: Hepatocellular Carcinoma, Unresectable, Transarterial Chemoembolization, Immunotherapy, Anti-Angiogenic Therapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.11, November 20, 2025

  ABSTRACT: Unresectable hepatocellular carcinoma (HCC) is a highly prevalent malignancy with a poor prognosis. Because it is often diagnosed at an advanced stage and treatment options are limited, it poses a serious threat to patient health. Traditional modalities such as surgical resection and various local therapies have limited applicability for most patients, underscoring the urgent need for more effective systemic strategies. In recent years, triple therapy combining transarterial chemoembolization (TACE), immune checkpoint inhibitors, and anti-angiogenic therapy has become a focus of investigation. This approach has shown potential to improve tumor control and patient survival. This review synthesizes the latest clinical trial data and foundational research on TACE combined with immunotherapy and anti-angiogenic therapy for unresectable HCC and outlines prospects for future development.